Equasens

EQS

Equity

ISIN FR0012882389 / Valor 29127567

Euronext - Euronext Paris (2025-11-21)

EUR 41.25+0.73%

Equasens
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Equasens Group operates at the intersection of healthcare and technology, focusing on enhancing patient care through improved communication and data sharing among healthcare professionals and institutions. The company is structured into five divisions, each targeting a strategic area within the healthcare sector, including outpatient and hospital care services. As a leading provider of Healthcare IT solutions, Equasens develops software and innovative equipment designed to streamline the daily operations of healthcare providers. By facilitating the exchange of healthcare data between independent professionals and healthcare establishments, the company aims to improve the quality of patient care. This is achieved by fostering better coordination and integration across various segments of the healthcare system, thereby addressing the complexities of the City-Hospital-Medico-Social continuum.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In 2023, Equasens achieved a 2.6% increase in revenue, reaching €219.7 million. Like-for-like growth stood at 3.3%, driven by enhanced license sales from new mobile and SaaS solutions. However, pharmacy equipment sales declined due to higher financing rates.

Stable Net Profit

Net profit for 2023 remained steady, increasing by 0.4% to €48.9 million. The net profit attributable to the Group rose by 1.4%, supported by a strong operating margin of 25.4%.

Strategic Acquisitions

Equasens strengthened its market presence in Germany through the acquisition of ADV, enhancing its PHARMAGEST Division. Additionally, the acquisition of a 70% stake in DIGIPHARMACIE positions the company to lead in digital healthcare solutions across Europe.

Strong Financial Position

The company maintains a robust cash position with a cash flow of €137 million and a net-debt-to-equity ratio of -29.7%. This financial stability supports ongoing investments and strategic initiatives.

Summarized from source with an LLMView Source

Key figures

1.35%1Y

-45.5%3Y

-56.6%5Y

Performance

37.1%1Y

35.9%3Y

33.6%5Y

Volatility